When a rheumatologist prescribes Humira instead of a biosimilar, or an oncologist chooses Ocrevus over a generic alternative, it’s not because they’re ignoring cost-it’s because they’ve seen what happens when patients switch. For specialists treating complex, life-altering conditions like multiple sclerosis, rheumatoid arthritis, or rare cancers, brand-name drugs aren’t just preferred-they’re often the only reliable option. And the numbers back this up: specialty drugs, which make up just 6.2% of all prescriptions, account for 71.1% of total U.S. prescription drug spending. That’s not a typo. One out of every $1.40 spent on meds goes to a drug used by less than 1 in 20 patients.
What Makes a Drug ‘Specialty’?
Specialty drugs aren’t just expensive. They’re defined by three things: high cost, complex use, and tight distribution. The Centers for Medicare & Medicaid Services (CMS) sets the bar at $670 per month, but more than half of these drugs cost over $100,000 a year. Many require injections or infusions, special refrigeration, or daily monitoring. Some, like Jakafi or Ofev, are used for conditions where there’s literally no other treatment that works. A patient with pulmonary fibrosis doesn’t get to try three different pills until one sticks-they need the right one, right away.
These aren’t your run-of-the-mill statins or blood pressure pills. They’re biologics, gene therapies, or targeted cancer drugs developed over decades. They’re not mass-produced. They’re made in controlled environments, shipped in specialized coolers, and tracked from manufacturer to patient. That’s why only a handful of pharmacies are certified to handle them-and why switching isn’t as simple as swapping a brand for a generic.
Why Specialists Don’t Switch to Biosimilars or Generics
You’d think with biosimilars available for drugs like Humira and Enbrel, doctors would jump at the cheaper option. But they don’t. And here’s why: patients aren’t interchangeable.
A 2023 Medscape survey of 1,200 specialists found that 79% of rheumatologists and 82% of oncologists say prior authorization delays and formulary restrictions directly impact patient outcomes. One rheumatologist in Chicago told a patient who switched to a biosimilar that her joint pain returned within three weeks. She had to go back on Humira-and her insurance denied it. She ended up paying $850 a month out-of-pocket. That’s not rare. On the Medicare Rights Center forum, patients regularly share stories like hers: ‘My doctor says biosimilars aren’t appropriate for me,’ they write. Not because they’re being pushy, but because their condition is too unpredictable.
Studies show that up to 30% of branded drug dispensing is requested by prescribers or patients themselves. That’s not because they’re being influenced by drug reps-it’s because they’ve seen the consequences of switching. A 2021 JAMA Network Open study found that when patients switched from brand to generic for specialty drugs, relapse rates increased in autoimmune conditions. No one wants to be the doctor who says, ‘It’s cheaper, but your disease might flare.’
The Financial Pressure Is Real-For Everyone
It’s easy to blame drug companies for high prices. But the system is layered. The Federal Trade Commission’s 2025 report revealed something startling: pharmacy benefit managers (PBMs) like CVS Caremark, Express Scripts, and OptumRx were marking up specialty generic drugs by thousands of percent. In some cases, they paid $10 for a vial and billed the insurer $1,200. That’s not the manufacturer’s doing-that’s the middleman.
And it’s not just patients who suffer. Health systems are drowning. UnitedHealthcare reported that specialty drugs make up 53% of total pharmacy spend, even though they’re only 3% of claims. Hospitals now have entire departments just to manage prior authorizations. Physicians spend an average of 13.4 hours a week on paperwork just to get one drug approved. That’s more time than most spend on patient education.
Patients aren’t unaware of this. On Reddit, u/ChronicWarrior42 wrote: ‘I pay $1,200 a month for Ocrevus. My insurance covers 80%, but my deductible is $7,000. My specialist says there are no alternatives that work for my mutation. So I pay.’ That’s not greed. That’s survival.
Why Generics Don’t Work the Same Way Here
For a pill like Lipitor, a generic works because it’s chemically identical. But biologics? They’re made from living cells. Even if a biosimilar is approved as ‘similar,’ small differences in manufacturing can change how the immune system responds. In autoimmune diseases, even a tiny shift can mean a flare-up, hospitalization, or permanent damage.
The FDA allows biosimilars, but doesn’t require interchangeability studies for every condition. So a biosimilar approved for rheumatoid arthritis might not have been tested for psoriatic arthritis. A specialist won’t risk it. They’ve seen patients lose mobility, vision, or lung function after switching. There’s no clinical trial that says, ‘It’s safe for everyone.’ And in medicine, when evidence is thin, caution wins.
How the System Forces Prescribers’ Hands
Specialists don’t choose brand drugs because they’re paid to. The ProPublica analysis from 2016 found that doctors who received over $5,000 from drug companies prescribed brand-name drugs 50% more often. But here’s the twist: even doctors who received nothing still preferred brands. Why? Because the system is stacked.
PBMs control formularies. They decide which drugs are covered and at what tier. Many plans put brand-name specialty drugs on Tier 3 or 4, while biosimilars are on Tier 2. Sounds fair-until you realize the patient’s out-of-pocket cost for the biosimilar is still $700 a month because of the way the PBM structures the copay. The brand? $50. Why? Because the manufacturer has a patient assistance program. The biosimilar? None.
So the doctor doesn’t pick the brand because it’s more profitable. They pick it because it’s the only one the patient can actually afford to take.
What’s Changing-and What’s Not
The Inflation Reduction Act of 2022 let Medicare negotiate prices for some high-cost drugs. So far, it’s only targeted a handful, like insulin and a few cancer drugs. But experts say the next wave will hit specialty drugs hard. Drugs like Jakafi, Ofev, and Xtandi are likely targets in upcoming rounds. That could bring prices down-but only if manufacturers don’t pull the drug from Medicare entirely.
Meanwhile, the FTC is pushing for transparency. Their 2025 report called PBM markups ‘a fundamental distortion.’ Senator Bernie Sanders introduced the Specialty Drug Price Transparency Act in February 2025 to force PBMs to report their net prices. If passed, it could change how these drugs are priced.
But until then, specialists keep prescribing what works. Because for their patients, the stakes aren’t about cost-they’re about survival.
What Patients and Providers Need to Know
- Brand-name preference isn’t about greed-it’s about risk. For many, switching means relapse.
- Generics and biosimilars aren’t always interchangeable, especially in autoimmune or rare diseases.
- Prior authorization delays can cost weeks of treatment. One study found 42% of specialty drug starts are delayed by over a week.
- Financial assistance programs exist. The National Organization of Rare Disorders (NORD) helped 45,000 patients in 2023.
- Ask your provider: ‘Is there a patient assistance program for this drug?’ Many don’t know about them.
Why do specialists prescribe brand-name drugs even when generics are available?
Specialists prescribe brand-name drugs because many specialty conditions-like multiple sclerosis, rheumatoid arthritis, or rare cancers-have no proven alternatives. Biosimilars may be approved, but they haven’t been tested in every patient subtype. A switch that works for one person might trigger a relapse in another. Doctors base decisions on real-world outcomes, not just price tags.
Are brand-name specialty drugs really that much more expensive than generics?
Yes-by orders of magnitude. A specialty brand can cost $38,000 per year per patient, while non-specialty drugs average $492. Even when a biosimilar exists, the out-of-pocket cost can be higher due to how insurance plans and pharmacy benefit managers (PBMs) structure copays. Some PBMs mark up generic specialty drugs by thousands of percent, making the ‘cheaper’ option more expensive for patients.
Do drug companies influence specialists to prescribe brand-name drugs?
Some do-ProPublica found doctors receiving over $5,000 from pharma companies prescribed brand-name drugs 50% more often. But many specialists prescribe brands even without payments. Their decision is based on clinical experience: patients who switched to biosimilars often had worse outcomes. The real driver isn’t marketing-it’s fear of disease flare-ups and irreversible damage.
Can patients get help paying for specialty drugs?
Yes. Most brand-name manufacturers offer patient assistance programs that can reduce or eliminate out-of-pocket costs. Nonprofits like NORD helped 45,000 patients in 2023. But these programs are often hard to find. Patients need to ask their specialist or pharmacist: ‘Is there a patient support program for this drug?’ Many don’t know it exists.
Why do prior authorizations take so long for specialty drugs?
Specialty drugs require more documentation because they’re expensive and often used for complex conditions. Insurers demand proof that less costly options have failed, that the patient meets strict criteria, and that the prescribing provider is qualified. The average physician spends 13.4 hours a week on prior authorizations-78% of that time is for specialty drugs. Delays of over a week are common, and for someone with a rapidly progressing disease, that’s dangerous.
